Pocapavir (Synonyms: SCH-48973; V-073)

Name: Pocapavir
Brand: MedChemExpress
SKU: HY-104074
Rating: 5.0 (5 reviews)

Cat. No.: HY-104074 Purity: 99.59%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections.

For research use only. We do not sell to patients.

Pocapavir Chemical Structure

CAS No. : 146949-21-5

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Pocapavir:

Pocapavir-d₃ Get quote
Pocapavir (Standard) Get quote

5 Publications Citing Use of MCE Pocapavir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
H1-HeLa	CC₅₀	> 100 μM Compound: 29	Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay	[PMID: 28581749]
HeLa	CC₅₀	16 μM Compound: 29	Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay	[PMID: 28581749]
HeLa	EC₅₀	0.08 μM Compound: 29	Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay	[PMID: 28581749]
LLC-MK2	EC₅₀	0.003 μM Compound: V-073	Antiviral activity against Poliovirus P712 serotype PV2 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus P712 serotype PV2 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.007 μM Compound: V-073	Antiviral activity against Poliovirus Lansing serotype PV2 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus Lansing serotype PV2 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.008 μM Compound: V-073	Antiviral activity against Poliovirus 10693 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10693 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.008 μM Compound: V-073	Antiviral activity against Poliovirus 10695 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10695 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.009 μM Compound: V-073	Antiviral activity against Poliovirus 10234 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10234 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.01 μM Compound: V-073	Antiviral activity against Poliovirus 10220 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10220 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.01 μM Compound: V-073	Antiviral activity against Poliovirus 10223 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10223 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.011 μM Compound: V-073	Antiviral activity against Poliovirus 10237 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10237 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.014 μM Compound: V-073	Antiviral activity against Poliovirus 10238 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10238 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.014 μM Compound: V-073	Antiviral activity against Poliovirus 10239 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10239 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.014 μM Compound: V-073	Antiviral activity against Poliovirus 10694 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10694 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.015 μM Compound: V-073	Antiviral activity against Poliovirus 10222 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10222 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.015 μM Compound: V-073	Antiviral activity against Poliovirus 10240 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10240 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.016 μM Compound: V-073	Antiviral activity against Poliovirus PV2-P712 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus PV2-P712 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.017 μM Compound: V-073	Antiviral activity against Poliovirus 10225 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10225 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.017 μM Compound: V-073	Antiviral activity against Poliovirus 10242 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10242 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.017 μM Compound: V-073	Antiviral activity against Poliovirus PV1-LSc/2ab serotype PV1 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus PV1-LSc/2ab serotype PV1 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.018 μM Compound: V-073	Antiviral activity against Poliovirus 10235 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10235 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.018 μM Compound: V-073	Antiviral activity against Poliovirus 10691 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10691 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.018 μM Compound: V-073	Antiviral activity against Poliovirus Brunhilde serotype PV1 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus Brunhilde serotype PV1 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.019 μM Compound: V-073	Antiviral activity against Poliovirus 10226 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10226 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.019 μM Compound: V-073	Antiviral activity against Poliovirus 10227 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10227 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.019 μM Compound: V-073	Antiviral activity against Poliovirus 10232 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10232 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.02 μM Compound: V-073	Antiviral activity against Poliovirus 10229 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10229 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.02 μM Compound: V-073	Antiviral activity against Poliovirus PV3-Leon serotype PV3 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus PV3-Leon serotype PV3 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.021 μM Compound: V-073	Antiviral activity against Poliovirus 10668 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10668 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.023 μM Compound: V-073	Antiviral activity against Poliovirus 10219 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10219 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.024 μM Compound: V-073	Antiviral activity against Poliovirus 10233 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10233 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.026 μM Compound: V-073	Antiviral activity against Poliovirus MEF-1 serotype PV2 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus MEF-1 serotype PV2 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.027 μM Compound: V-073	Antiviral activity against Poliovirus 10221 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10221 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.028 μM Compound: V-073	Antiviral activity against Poliovirus 10231 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10231 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.029 μM Compound: V-073	Antiviral activity against Poliovirus 10236 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10236 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.029 μM Compound: V-073	Antiviral activity against Poliovirus 10690 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10690 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.029 μM Compound: V-073	Antiviral activity against Poliovirus 10692 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10692 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.029 μM Compound: V-073	Antiviral activity against Poliovirus 10805 serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10805 serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.036 μM Compound: V-073	Antiviral activity against Poliovirus 10230 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10230 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.038 μM Compound: V-073	Antiviral activity against Poliovirus 10243 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10243 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.042 μM Compound: V-073	Antiviral activity against Poliovirus 10689 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10689 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.042 μM Compound: V-073	Antiviral activity against Poliovirus 10804 serotype PV3 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10804 serotype PV3 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.062 μM Compound: V-073	Antiviral activity against Poliovirus Saukett serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus Saukett serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.069 μM Compound: V-073	Antiviral activity against Poliovirus 10224 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10224 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.076 μM Compound: V-073	Antiviral activity against Poliovirus Mahoney serotype PV1 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus Mahoney serotype PV1 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.083 μM Compound: V-073	Antiviral activity against Poliovirus 10241 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10241 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.109 μM Compound: V-073	Antiviral activity against Poliovirus Leon serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus Leon serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.126 μM Compound: V-073	Antiviral activity against Poliovirus 10228 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10228 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]

In Vitro

Pocapavir belongs to a picornavirus antiviral mechanistic class called capsid inhibitors that block virus uncoating and viral RNA release into cells, which in turn prevents virus replication^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

423.72

Formula

C₂₁H₁₇Cl₃O₃

CAS No.

146949-21-5

Appearance

Solid

Color

White to off-white

SMILES

ClC1=C(OCC2=CC=C(COC3=CC=C(OC)C=C3Cl)C=C2)C(Cl)=CC=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (236.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3600 mL	11.8002 mL	23.6005 mL
5 mM	0.4720 mL	2.3600 mL	4.7201 mL
10 mM	0.2360 mL	1.1800 mL	2.3600 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.59%

Select Batch:

Data Sheet (271 KB) SDS (393 KB)

COA (246 KB) HNMR (258 KB) LCMS (105 KB)

Handling Instructions (2659 KB)

References

[1]. Collett MS, et al. Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model. J Infect Dis. 2017 Feb 1;215(3):335-343. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3600 mL	11.8002 mL	23.6005 mL	59.0012 mL
	5 mM	0.4720 mL	2.3600 mL	4.7201 mL	11.8002 mL
	10 mM	0.2360 mL	1.1800 mL	2.3600 mL	5.9001 mL
	15 mM	0.1573 mL	0.7867 mL	1.5734 mL	3.9334 mL
	20 mM	0.1180 mL	0.5900 mL	1.1800 mL	2.9501 mL
	25 mM	0.0944 mL	0.4720 mL	0.9440 mL	2.3600 mL
	30 mM	0.0787 mL	0.3933 mL	0.7867 mL	1.9667 mL
	40 mM	0.0590 mL	0.2950 mL	0.5900 mL	1.4750 mL
	50 mM	0.0472 mL	0.2360 mL	0.4720 mL	1.1800 mL
	60 mM	0.0393 mL	0.1967 mL	0.3933 mL	0.9834 mL
	80 mM	0.0295 mL	0.1475 mL	0.2950 mL	0.7375 mL
	100 mM	0.0236 mL	0.1180 mL	0.2360 mL	0.5900 mL

Pocapavir Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Pocapavir (Synonyms: SCH-48973; V-073)

Customer Review

Other Forms of Pocapavir:

5 Publications Citing Use of MCE Pocapavir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Pocapavir Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Pocapavir (Synonyms: SCH-48973; V-073)

Customer Review

Other Forms of Pocapavir:

Pocapavir Related Antibodies

5 Publications Citing Use of MCE Pocapavir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Pocapavir Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Pocapavir Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report